Supplies of bladder cancer drug are dwindling

(By Alia Paavola for Becker’s Hospital Review)

Supplies of BCG, a critical immunotherapy drug that treats bladder cancer, are dwindling, according to a STAT news report.

The shortage of the medication is being felt across the nation, as hospitals find it harder to obtain it. Smaller clinics already have run out of the drug, while larger hospitals like New York City-based Memorial Sloan Kettering Cancer Center, have changed their policies on administering the drug to prioritize newly diagnosed patients.  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.